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ABSTRACT
Introduction: Available preventive drug treatments for migraine lack complete efficacy and often have
unpleasant adverse effects. Hence, their clinical utility and therapeutic adherence are limited. Noninvasive
neurostimulation methods applied over various peripheral sites (forehead, mastoid, upper arm, cervical vagus
nerve) have raised great interest because of their excellent efficacy/tolerance profile. Among them external
trigeminal nerve stimulation (eTNS) was first to obtain FDA approval for migraine therapy.
Areas covered: All clinical trials of eTNS as preventive or acute migraine treatment published in
extenso or presented at congresses are reviewed. The paper analyzes neuroimaging and neurophysio-
logical studies on mechanisms of action of eTNS. As many of these studies point toward the anterior
cingulate cortex (ACC) as a likely eTNS target, the paper scrutinizes the available literature on the ACC
implication in migraine pathophysiology.
Expert commentary: eTNS is a viable alternative to standard pharmacological antimigraine strategies
both for prevention and abortive therapy. eTNS could chiefly exert its action by modulating the
perigenual ACC, which might also be of interest for treating other disorders like fibromyalgia or
depression. It remains to be determined if this might be a common mechanism to other peripheral
noninvasive neurostimulation methods.
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1.1. Pharmacotherapy of migraine
Although cognitive-behavioral therapies can be useful as add-
on therapies in some patients, currently, migraine is mostly
managed with pharmacological treatments. Acute migraine
drugs like analgesics, nonsteroidal anti-inflammatory drugs
(NSAIDs) and triptans [1] are used to interrupt a migraine
attack and allow patients to recover normal functioning as
soon as possible [2]. Triptans, the agonists of 5-HT1B/D sero-
tonin receptors, are up to now the most effective drugs for
severe attacks. They can, however, induce class-specific side
effects like chest, face, and limb pain or discomfort that are
difficult to tolerate by many patients. Moreover, they are
vasoconstrictors and contraindicated in case of comorbid car-
dio- or cerebrovascular pathology. Migraine patients with fre-
quent attacks or attacks not responding adequately to acute
treatments are in need of a preventive antimigraine treatment
able to modify the disease course by decreasing attack fre-
quency and intensity [3] so that excessive consumption of
acute antimigraine drugs does not lead to headache chronifi-
cation, i.e. so-called medication overuse headache, which wor-
sens the patients’ condition [4].
Effective preventive drugs include beta-blockers without
intrinsic sympathetic activity, certain calcium channel blockers
like flunarizine or verapamil, sartans, the antiepileptics topir-
amate and valproate, and possibly amitriptyline [5], as well as
nutraceuticals like riboflavin and coenzyme Q10 [6]. Preventive
migraine drugs have only partial efficacy with an overall
50–60% success rate and, except for the nutraceuticals, they
tend to cause moderate to severe side effects, frequently
leading to dissatisfaction and discontinuation by the patients
[7–9]. Consequently, 80% of patients are willing to change
their current medication for a treatment with similar efficacy
but fewer side effects [10]. The therapeutic efficacy of
migraine preventives decreases sharply with migraine chron-
ification, which explains why up to 50% of chronic migraine
patients discontinue their prophylactic drug treatment after
2 months [11].
1.2. Neurostimulation as an alternative antimigraine
treatment
The shortcomings of pharmacological migraine management
and technological advances have allowed neurostimulation
methods to emerge as credible alternative antimigraine
treatments.
Since the 1990s, stimulation of pericranial nerves through
percutaneously implanted electrodes was found effective for
the treatment of various headaches in various studies [12,13].
Occipital nerve stimulation (ONS) was reported beneficial for
chronic migraine in some, but not all, sham-controlled trials,
but globally the effect size was modest [14–16]. Combining
percutaneous ONS with supraorbital nerve stimulation (SNS)
was claimed to have a better effect, but randomized con-
trolled trials are lacking [17]. These neurostimulation methods
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using implanted electrodes may cause various adverse effects
chiefly due to local infections, lead displacement or frequent
battery replacement, but their major drawback is that they are
invasive and indicated only for the most disabled, drug-refrac-
tory patients with very frequent and severe migraine
attacks [18].
With the advent of noninvasive transcutaneous stimulators
neurostimulation therapy became applicable to all migraine
patients irrespective of their level of disability or drug-refrac-
toriness [19]. In recent years various transcutaneous stimula-
tion methods were reported to be effective in migraine
treatment despite striking differences in targets: bilateral mas-
toid [20], cervical vagus nerve [21], or skin at the wrist [22].
Several studies of noninvasive neurostimulation in the trigem-
inal territory showing beneficial effects in various headache
types were published as early as 1985 [23–26]; among them,
the single-blinded, placebo-controlled trial by Solomon and
Guglielmo [23] appears to be the most convincing. Two dec-
ades later, technological advances permitted to produce a
portable, affordable and user-friendly external trigeminal neu-
rostimulator (eTNS) called Cefaly® (Cefaly Technology sprl,
Seraing, Belgium). This device delivers electrical pulses to the
forehead branches of the first division of the trigeminal nerve,
the ophthalmic nerve, though it can also be applied over the
greater occipital nerves via a suboccipital band. The pulses are
rectangular biphasic impulses with an electrical mean equal to
zero, impulse width of 250 µs, frequency of 60–120 Hz, max-
imum intensity of 16 mA with an increment from 1 to 16 mA
over 14 min. The device has an inbuilt software to record time
of use. During the last 4 years several clinical trials have
explored the therapeutic effect of eTNS both for the preven-
tive and the acute treatment of migraine. We will review these
trials as well as studies aimed at determining the mode of
action of eTNS in migraine.
2. Clinical eTNS trials in migraine
For the sake of comprehensiveness, all clinical data of eTNS
with this device in migraine that are in the public domain are
displayed in Table 1, including manuscripts submitted for
publication and abstracts.
2.1. Migraine prevention
Eight studies have addressed the preventive effect eTNS, ran-
ging from an early small pilot trial to a randomized sham-
controlled trial [27–34]. In all of them there was a decrease in
migraine attack frequency after daily stimulation for time
periods between 1 and 4 months, both in episodic and chronic
migraine (two open label trials). We will focus briefly on the
PREMICE trial [28] where eTNS (n = 34, 250 µs, 60 Hz, 16 mA)
was compared to sham stimulation (n = 33, 30 µs, 1 Hz, 1 mA)
for a 3-month treatment period. After using the device with
the active stimulation protocol 38.1% of patients had a ≥ 50%
reduction in monthly migraine days compared to pretreat-
ment baseline, while only 12.1% of patients did so with the
sham stimulation. There were no adverse events except for the
frontal paresthesias that are known to occur with electrical
stimuli. Up to now no trial comparing eTNS with a preventive
drug treatment is available. Topiramate, presently one of the
most effective drugs, is more efficacious than eTNS in the
pooled analysis of placebo-controlled trials reaching a 45.3%
of 50% responder rate [29], but it is hampered by unpleasant
side effects and low tolerability. For comparison, 1 out of 4
patients taking topiramate abandoned the drug because of
intolerable side effects [29], while in a survey of 2313 patients
using eTNS 4.3% reported one or more adverse effects, chiefly
intolerance to the forehead paresthesias (1.25%) and 2%
stopped treatment because of an adverse effect [30]. As a
result of the PREMICE trial, the device was the first medical
device to get approval from the FDA in 2014 for the preven-
tive treatment of migraine.
2.2. Acute migraine treatment
Since it was marketed, this eTNS device contains a stimulation
protocol with a 100 Hz frequency recommended for attack
treatment based on a pilot study [27]. In clinical practice many
migraineurs have been using this protocol to treat their
attacks effectively before evidence-based data became avail-
able. In an internet survey, 88.6% of 413 regular users applied
the device in 71.8% of attacks, which allowed reducing acute
migraine drug use in 42.6% of them [31]. Chou et al. [32,33]
were first to scientifically assess efficacy of eTNS for acute
migraine treatment in patients stimulated for 1 h in the hos-
pital for an untreated attack that had started ≥3 h before. In
the initial open study 77% of patients had ≥50% pain relief at
1 h; in the subsequent multicenter, sham-controlled ACME trial
[32,33], 63% of patients reached this end point compared to
31% in the sham arm and 29% were pain-free at 1 h versus 6%
with the sham stimulation. This beneficial effect was con-
firmed in a recent open label study of 48 patients who treated
a moderate to severe attack at home for 2 h [34]: 35.4% were
pain-free at the end of the stimulation. The 2 h pain-free rates
with eTNS are comparable, or even superior, to those reported
in recent drug trials of sumatriptan nasal powder (34.3%) [35],
the 5-HT1F agonist lasmiditan (28%) [36] or the CGRP receptor
antagonist ubrogepant (25.5%) [37]. They are also superior to
those found in open studies of noninvasive cervical vagus
nerve stimulation (21% and 22.9%) [38,39].
3. Mode of action
Some recent studies have shed some light on possible
mechanisms by which eTNS may reduce migraine attack fre-
quency and headache during an attack. eTNS can have an
effect on the peripheral and the central nervous system.
Transcutaneous electrical nerve stimulation (TENS), in use
since many years to relieve pain [40], is thought to act in part
by blocking nociceptive traffic at the segmental level by acti-
vating large Aβ afferents according to the gate control theory
[41,42]. By analogy, pericranial nerve stimulation could have
the same effect by activating somatic afferents from the tri-
geminal territory or C2 dermatoma that are known to con-
verge with visceral trigeminovascular afferents on spinal
trigeminal nucleus second-order nociceptors. This might
apply to low intensity–high frequency TENS. Acupuncture-
like high intensity–low frequency TENS and high intensity–
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high frequency TENS, resembling the Cefaly® stimulation pro-
tocols, more likely engage extrasegmental mechanisms such
as activation of subcortical pain control centers [43].
We will review the evidence for peripheral, segmental and
suprasegmental mechanisms possibly involved in the antimi-
graine eTNS effects.
3.1. Peripheral nervous system mechanisms
As opposed to the visceral afferents of the trigeminovascu-
lar system, somatic nociceptive afferents of the first division
of the trigeminal nerve are not supposed to play a major
role in migraine headache pathophysiology. Nonetheless,
branches of meningeal nociceptive fibers were recently
found to emerge at the level of cranial emissary canals
and fissures and to innervate the cranial periosteum and
muscles mainly in the temporal, parietal, and occipital areas
[44]. Because of its anatomical position and its reduced
surface, it seems thus unlikely that the device activates
such extracranial meningeal afferents.
High intensity–low frequency TENS causes intense, but not
uncomfortable, muscle contraction able to activate muscle affer-
ents and to produce analgesia [40]. Given the small size of fore-
head muscles under the stimulator, this probably is not relevant
for the device’s antimigraine effects. Interestingly, in chronic
migraine patients eTNS caused an increase of median frequency
and amplitude of the electromyographic signal in anterior tem-
poralis, auricularis posterior and middle trapezius muscles [45]. It




of patients Outcome References
Open-pilot
3 months



















≥50% responder rate: 81% Russo et al.
J Head Pain 2015 [82]
Survey
of prospective company registry
2313 migraineurs testing the Cefaly® 54.4% satisfied & willing to buy after a 58-day
test
4.4% report adverse events (2.03%: local
intolerance)
Magis et al.
J Head Pain 2013 [30]
Open
4 months
23 chronic migraine patients with or
without medication overuse
50% reduction in monthly migraine days: 35% Di Fiore et al.
Neurol Sci 2017 [83]
Open, multicenter,
3 months




50% responder rate: 1/31
2.6 headache days
3.9 days with acute medication
Vikelis et al.






50% reduction in attack frequency
Decrease in intensity & duration
Przeklasa-Muszynska
et al.




58 chronic migraine patients Headache days:
−24% (nonpermanent headache, n = 34);







10 episodic MO patients
3 attacks
Attack outcome at 30 min:
12% – total relief
45% – partial relief







16 episodic MO patients 46% reduction of headache




In-hospital 1 h treatment
Attack duration ≥3 h
30 episodic MO patients At 1 h:
57% reduction in head pain







88.6% use the device in 71.8% of attacks
42.6% device-treated attacks with reduction of
acute migraine drugs
Penning & Schoenen










VAS: −59% (sham −30%)
29% pain-free
(sham: 6%)






Moderate to severe attacks of ≤ 4h
duration
59 episodic migraine patients








MO: migraine without aura; VAS; visual analogue scale; mITT: modified intention-to-treat.
EXPERT REVIEW OF NEUROTHERAPEUTICS 547
is doubtful that this is relevant for the mode of action of the
device, themore so that there was no increase in frontalis muscle
activity and that pericranial muscles have no role in the patho-
physiology of chronic migraine [46].
3.2. Central effects
The changes induced by single or multiple sessions of eTNS on
central nervous system activities are summarized in Table 2.
Several experimental studies have not confirmed the
hypothesis that pericranial nerve stimulation might decrease
trigeminal nociception by a segmental gate control.
Stimulation of the greater occipital nerve increased, rather
than decreased, activation by dural afferents of trigemino-
cervical nociceptive neurons in rats [47] and suboccipital
3 Hz nociceptive stimulation had no effect in humans on the
nociceptive blink reflex (nBR), a surrogate marker of spinal
trigeminal nucleus excitability [48].
By contrast, nBR amplitude and homotopic pain ratings were
found lastingly diminished by supraorbital 1 Hz noxious stimu-
lation in normal subjects and this was attributed to long-term
depression of second order nociceptors in the spinal trigeminal
nucleus [49]. An accompanying editorial [50] suggested that
low frequency–high intensity acupuncture-like electrical stimu-
lation might be able to attenuate the long-term potentiation of
dorsal horn nociceptive synapses that contribute to hyperalge-
sia and allodynia and thus very promising for pain therapy.
Contrary to the previous study [49], eTNS uses high fre-
quency stimuli. Nonetheless, when the effect of one 20-min
session of stimulation (60 Hz, 16 mA) was tested on the nBR
in 10 migraine patients recruited for the abovementioned pilot
study [27], there was a mild, but significant decrease of nBR
amplitude and a more pronounced decrease of habituation.
One session of eTNS in migraine patients between attacks
also significantly decreased amplitude of contact heat-evoked
potentials (CHEPs) when they were obtained by thermonoci-
ceptive stimuli to the frontal skin, but not after stimulating the
wrist [51]. The fact that eTNS reduces CHEPs homotopically
suggests that it acts via trigemino-specific segmental or supra-
segmental pathways. Since the eTNS effect is greater on CHEPs
than on nBR, a suprasegmental mechanism could be more
likely.
Along the same line, amplitude of laser heat evoked
cortical responses was also significantly reduced after a
20min-session of real eTNS (250 μsec, 60 Hz, 16 mA) but
not after sham stimulation (2 mA) both in migraineurs
interictally and in healthy controls [52]. In this study, eTNS
was associated with reduced evoked EEG activity in anterior
cingulate cortex (ACC).
The confirmation that eTNS with this device might have
central effects came from a double-blinded, cross-over,
sham-controlled trial in 30 healthy volunteers measuring
vigilance and attention with psychomotor tests at the end
of a 20-min eTNS session at 2.5 or 120 Hz and of a session
with sham stimulation (1 mA) [53] (see Table 2). In this
study, there was a significant decrease in vigilance and
attention during high frequency eTNS. Whether such an
effect contributes to the therapeutic benefit of the eTNS
device is uncertain, as for migraine therapy the stimulation
frequencies used for acute and preventive treatment are
lower, respectively 100 and 60 Hz. The commercialized
device contains, however, a high frequency stimulation pro-
gram (120 Hz) that certain patients use for relaxation.
Using fluoro-deoxyglucose (FDG)-PET we have analyzed
changes in brain metabolism in 14 migraine without aura
patients before, after one 20-min session and after 3 months
of daily 20-min sessions of eTNS with the device (60 Hz,
16 mA) [54]. In patients compared to healthy controls, base-
line glucose uptake was significantly decreased bilaterally in
orbitofrontal (OFC), rostral anterior cingulate cortex (rACC),
and temporal lobe. This hypometabolism was not modified
after one eTNS session. However, in 10 patients who treated
themselves for 3 months and were compliant to eTNS as
revealed by the inbuilt software, monthly migraine days and
attack frequency significantly decreased, and metabolism
normalized in pretreatment hypometabolic areas
Table 2. Studies on central effect of eTNS with the Cefaly®.
CENTRAL EFFECTS OF eTNS WITH CEFALY®
Study protocol Method Result Authors
3-month treatment
60 Hz, 250 μs, 16 mA
10 episodic MO (compliant)
20 HC
FDG-PET
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Before eTNS: greater noxious THS-induced ACC
activation in MO
After eTNS: significant ↙ of ACC activation
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Sasso D’Elia et al.
Cephalalgia 2013
(abstract) [87]
FDG-PET: fluorodeoxyglucose positron emission tomography; OFC: orbitofrontal cortex; ACC: anterior cingulate cortex; fMRI BOLD: functional magnetic resonance
imaging blood oxygen-level dependent; HC: healthy controls; THS: trigeminal heat stimulus; LEPs: laser evoked potentials; CHEPs: contact heat evoked potentials.
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(Figure 1). The change in rACC metabolism combined to the
reduction of migraine attack frequency overtime during
eTNS may be the consequence of a slow central neuromo-
dulatory action, similar to that of other peripheral nerve
stimulations (see [50] for a review). Interestingly, Russo
et al. [55] found that blood oxygen-level dependent
(BOLD) activation in perigenual ACC (pgACC) by a noxious
heat stimulus on the cheek was significantly greater in
migraine without aura patients than in healthy volunteers.
In a therapeutic study of the eTNS device, the same authors
[56] found that 2 months of eTNS in 20 migraineurs signifi-
cantly reduced the noxious heat-induced BOLD activation in
pgACC as well as migraine attack frequency proportionally
to the functional magnetic resonance imaging (fMRI)
changes (Figure 2).
Between attacks migraine patients have smaller early bursts of
high-frequency oscillations (HFO1) embedded in somato-sensory
evoked potentials than healthy controls [57]. HFO1 are thought to
be generated by action potentials in thalamocortical afferents and
hence to reflect interictal thalamocortical dysrhythmia inmigraine.
Late HFO (HFO2) are due to cortical (inhibitory) interneuron dis-
charges and of normal amplitude in migraine. Immediately after
one 20-min session of eTNS, SSEP HFO1 are significantly increased
for less than 5min, while there is no effect on HFO2 (Figure 3) [58].
Whether the interictal low thalamocortical activity may be related
to the low metabolism in medial frontal cortices, and its normal-
ization by eTNS to the metabolic enhancement found after eTNS,
remains to be determined. It is worth mentioning, however, that
the electrophysiological changes were recorded after a single
eTNS session, whereas the metabolic changes were found after
chronic treatment, i.e. 3 months of daily eTNS.
4. ACC: the common denominator?
Taken together, the studies described above and summarized
in Table 2 suggest that eTNS with the device acts predomi-
nantly at suprasegmental levels by modulating activity in
medial frontal cortical areas comprising the anterior cingulate
and OFC cortices. These areas exert multiple functions related
to decision-making, mood and the affective dimensions of
pain controlling in particular individual levels of central pain
modulation in healthy subjects [59]. They were found to dys-
function in chronic migraine [60], medication overuse head-
ache [61], and chronic cluster headache [62].
Schwedt et al. [63] have reviewed the data obtained with
functional MRI in migraine. An update of the literature review
on the topic depicted in Table 3 shows that the ACC, a major
target of eTNS as described above, was found abnormal in a
number of studies assessing brain morphology, connectivity, or
function. The pgACC is of particular interest, as its activity was
found modified by eTNS in three studies with convergent results
but with different methods, FDG-PET [54], fMRI [56], and pain-
related evoked potentials [52]. The pgACC has been implicated in
various functions and diseases. For instance, it plays a role in
Figure 1. Histogram of changes in monthly migraine attack frequency before and after 1, 2, and 3 months of Cefaly® eTNS treatment in 10 compliant migraine without
aura (MO) patients. Brain areas with significantly different glucose uptake on FDG-PET overlaid over an MRI anatomical map. Anterior cingulate cortex, orbitofrontal cortex
and temporal lobe were hypometabolic in patients before treatment compared to healthy controls; all these areas normalized after 3 months eTNS.
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several psychiatric disorders in which its dysfunction is asso-
ciated with a variant in the CACNA1C gene [64], but also in the
self and resting state activity in the default mode network where
it is modulated by glutamate [65,66]. With regard to migraine,
however, the most relevant pgACC function is the one related to
pain control where it mainly seems to be involved in the affective
and emotional dimension. The pgACC was overall less activated
on fMRI in chronic pain patients than in healthy controls in a
paradigm where subjects had to estimate perceived pain inten-
sity on pictures depicting human limbs in painful and non-pain-
ful situations [67]. It is thought to mediate in part the analgesic
effects of motor cortex stimulation [68] and to play a pivotal role
in the central opioïdergic pain control system. The pgACC is rich
in opioid receptors and selectively activated during opioid
[69,70], but also placebo analgesia [71], providing evidence that
both analgesic modalities aremediated by activation of descend-
ing antinociceptive pathways.
Admittedly, abnormalities of the pgACC are not specific to
migraine. In cluster headache, in particular, the pgACC was found
hypometabolic outside of a bout but its metabolism increased
during a bout [72]. The same authors using PET with the opioid
receptor ligand [11C]diprenorphine found an inverse relationship
between duration of the cluster headache disorder and opioid
receptor availability in pgACC and ipsilateral hypothalamus [73].
In drug-resistant chronic cluster headache patients, we have
shown in a FDG-PET study that metabolism in the pgACC is
increased in responders to chronic ONS compared to nonrespon-
ders [61]. In migraine and cluster headache, both neurovascular
disorders, it remains controversial whether the dysfunction of
descending pain control systems is a primary causative phenom-
enon or secondary to repeated painful attacks. Interestingly, both
cluster headache [74] and migraine [75] are accompanied by
hypothalamic activation as a possible generator of an attack. The
pgACC has strong connectivity with the hypothalamus [76], which
might thus explain why it is involved in both disorders.
Finally, the facts that involvement of the pgACC seems not
specific for migraine, nor limited to pain control, and that eTNS
can change its activity and thalamocortical circuits, may explain
why pericranial neurostimulation, including eTNS, was reported
to have also therapeutic effects in tension-type headache [77],
fibromyalgia [78], depression [79], and epilepsy [80]. Given that
transcranial stimulation methods are able to change activity in
underlying cortical and subcortical structures including the
pgACC, it remains to be determined if they have therapeutic
potentials in migraine. Based on this rationale and the above-
mentioned study showing pgACC activation in refractory chronic
cluster headache patients ameliorated by ONS [62], we have
recently found in a proof-of-concept trial that transcranial direct
current stimulation (tDCS) with a montage targeting the pgACC
also has beneficial therapeutic effects in those patients [81].
5. Expert commentary
We have reviewed published evidence showing that eTNS
with this device is effective for the preventive and the
acute treatment of migraine. Effect size for prevention is
Figure 2. BOLD responses induced in right ACC (Talairach coordinates (x, y, z: 12, 35, 7) by a thermo-nociceptive stimulus are increased in migraine without aura
(MO) patients (n = 20) before eTNS. They are significantly reduced after 2 months of daily eTNS. Insert: T-map of statistically significant differences between MO and
healthy controls overlaid onto a Talairach transformed Colin-27 T1 high-resolution anatomical template. Bar graphs of percent BOLD signal changes during noxious
trigeminal heat stimulation at 51°C in MO patients before and after eTNS (modified after Russo et al. 2017 [56]).
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somewhat lower compared to the available most effective
preventive drugs, but tolerability is far better. Published
studies on the mechanisms of action of eTNS suggest that
modulation of central brain areas involved in pain control,
in particular of the ACC, either directly or via changes in
thalamocortical activity, could be pivotal for the beneficial
clinical effects. A segmental action on the trigeminal sys-
tem in the brain stem may contribute to the beneficial
acute eTNS effect. We have analyzed the imaging literature
in migraine and were struck by the fact that the ACC was
found abnormal in most studies, be they focused on its
morphological, connectivity or functional properties. The
pgACC may thus be the crucial mediator of the device’s
therapeutic effects, which may explain why eTNS can miti-
gate other painful and non-painful conditions in which this
brain area has a pathophysiological role. Given that non-
invasive neurostimulation at very different sites such as
mastoids [20], upper limb [22] or vagus nerve in the neck
[21], appears to have comparable beneficial effects in
migraine, it seems worthwhile to explore modulation of
ACC as a common mechanism of action for noninvasive
peripheral neurostimulation.
6. Five-year view
Several clinical trials with this eTNS device are ongoing or
planned, exploring, for example, its utility in treating headache
in the emergency ward, in preventing the full development of a
migraine attack when applied at the very beginning of an attack,
or in mitigating withdrawal headache during theweaning period
in medication overuse headache. There are also plans to conduct
a randomized controlled trial in tension-type headache, but also
in other chronic pain syndromes like fibromyalgia and in epi-
lepsy. Evidence of efficacy should be sought for the suboccipital
eTNS that has shown promising results in open trials of chronic
migraine. The possible advantage of stimulating simultaneously
or alternatively the frontal and suboccipital regions has to be
investigated. It is also of great interest to develop a device
combining eTNS with transcranial direct current stimulation,
since the latter allows direct modulation of the cortical respon-
sivity known to be abnormal in migraine while the former seems
to act more generally on areas of the limbic and pain systems.
Despite the recent avenue of novel pharmacotherapies
for migraine with an excellent efficacy/tolerability profile
like the monoclonal antibodies against CGRP or its recep-
tor, it is likely that a niche for noninvasive
Figure 3. Upper: illustrative recording in a migraine patient of high frequency oscillations (HFO, 450–750Hz) in somato-sensory evoked potentials before
(pretreatment) and immediately (Post 1) and 5 min after (Post 2) one 20-min session of eTNS with the Cefaly®. HFO1: early burst reflecting thalamocortical
activity; HFO2: late burst reflecting discharges of inhibitory cortical neurons.
Lower: bar graph showing pre- and post-eTNS changes in HFO1 in a group of 10 migraine patients between attacks (mean ± SEM).
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neurostimulation methods as alternative or add-on thera-
pies in primary headaches will persist. The future will
determine which of the various methods is most valuable
and for each headache type.
Key issues
● External trigeminal neurostimulation (eTNS) with the
Cefaly® device has evidence for a preventive therapeutic
effect in episodic migraine as well as for an abortive effect
during migraine attacks. There is circumstantial evidence
for its beneficial effect in chronic migraine and tension-
type headache.
● Its efficacy/tolerability profile is excellent, exceeding that of
most drug treatments for headaches.
● Available data cannot exclude that eTNS device may have an
analgesic effect via a gating effect in the trigeminal pain
pathway.
● Recent imaging studies, however, suggest that its predo-
minant acute and chronic effect is modulation of activity
Table 3. Functional imaging studies showing anterior cingulate cortex alterations in migraine.
ANTERIOR CINGULATE CORTEX ALTERATIONS IN MIGRAINE
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in the anterior cingulate cortex (ACC), a crucial limbic
area belonging to the salience/pain network.
● A comprehensive literature review indicates that the ACC is
precisely an area found abnormal in most morphological or
functional imaging studies of migraine.
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